Studies have verified that α-SMA+ CAFs could promote tumor progression, confer therapeutic resistance and mediate immunosuppressive TME in multiple ways, such as paracrine and ECM remodeling [2, 10, 11]. Here, ACTA1 is linked to neoplasm.